Verily scoops up a fellow software maker as Amy Abernethy scales its clinical trials platform
Amy Abernethy now has a whole new set of tools to tap into as she scales up the clinical trial management platform at Verily.
The life sciences outfit — now officially a subsidiary of Alphabet on equal footing with Google — has acquired SignalPath for an undisclosed amount, giving it access to a system of digital solutions that make it easier to run clinical trials, and promise to simultaneously boost quality and efficiency.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.